WuXi AppTec sub­sidiary to man­u­fac­ture Io­vance’s sol­id tu­mor TIL ther­a­py in US

WuXi Ad­vanced Ther­a­pies (ATU) will man­u­fac­ture Io­vance’s re­cent­ly ap­proved Am­tagvi for ad­vanced melanoma, which was her­ald­ed as the first mod­ern cell ther­a­py to se­cure an ap­proval in sol­id tu­mors and al­so the first ap­proval for a tu­mor-in­fil­trat­ing lym­pho­cyte-based ther­a­py.

WuXi ATU — a cell and gene sub­sidiary of WuXi AppTec — will be the first third-par­ty man­u­fac­tur­er to pro­duce the in­di­vid­u­al­ized T cell ther­a­py for sol­id tu­mors for com­mer­cial use, the man­u­fac­tur­er not­ed. The prod­uct’s an­a­lyt­i­cal test­ing and man­u­fac­tur­ing will be at WuXi ATU’s site lo­cat­ed near Io­vance’s Cell Ther­a­py Cen­ter at Philadel­phia’s Navy Yard.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER